Researchers
John Chrivia, Peter Yacuik
Summary
Saint Louis University researchers have identified a novel transcriptional co-activator for CBP, designated as SRCAP, that is a Snf2 family member. As such it has ATPase activity. SRCAP is also capable of activating gene transcription without CBP. Moreover, SRCAP is capable of interacting with CBP, DEAD box helicases, adenoviral DBP protein, ß-actin, DNA and nuclear receptors.
SRCAP and the SRCAP-related reagents have utility for development of diagnostic tests designed to assess SRCAP activity in biological and clinical test samples. Additionally, SRCAP could be a therapeutic target for treatment of diseases that involve inappropriate transcriptional activation modulated by SRCAP or CBP including viral infections, cancer, and central nervous system disorders.
Intellectual Property Status
- U.S. utility patent 6,365,372